Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00401271
Recruitment Status : Completed
First Posted : November 20, 2006
Last Update Posted : March 7, 2007
Information provided by:
Otsuka Frankfurt Research Institute GmbH

Brief Summary:

The purpose of this trial is to evaluate the safety, efficacy and pharmacokinetics of 100mg, 200mg , 300mg and 400mg once daily of OPC-67683, administered orally for 14 consecutive days, in patients with uncomplicated, smear-positive pulmonary TB.

The four OPC-67683 treatment groups will comprise 12 patients each and the one standard therapy (Rifafour e-275) group six patients.

Trial 242-06-101 is an exploratory and not a confirmatory trial and as such no hypothesis will be tested statistically.

The control group, six patients treated with Rifafour, will serve as an control to confirm the microbiological assessments during the trial.

Condition or disease Intervention/treatment Phase
Pulmonary Tuberculosis Drug: OPC-67683 Drug: Rifafour e-275 Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Four Oral Doses of OPC-67683 in Patients With Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
Study Start Date : November 2006
Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis
U.S. FDA Resources

Primary Outcome Measures :
  1. TB bacterial load in sputum measured as colony forming units

Secondary Outcome Measures :
  1. Early Bactericidal Activity (EBA)
  2. Slope 0-14
  3. Tme to culture positivity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provide written, informed consent prior to all trial-related procedures.
  • Male and female patients aged between 18 and 64 years, inclusive.
  • Newly diagnosed, previously untreated, uncomplicated, smear positive, pulmonary TB.
  • A chest X-ray finding compatible with TB.
  • Sputum positive on direct microscopy for acid-fast bacilli (AFB) (at least 1+).
  • Able to produce an adequate volume of sputum (10mL or more estimated overnight production).
  • Female patients of childbearing potential must demonstrate a negative pregnancy test result. Furthermore they must agree to use a highly effective method of contraception.
  • Male patients must agree to use an adequate method of contraception.

Exclusion Criteria:

  • Poor general condition where no delay in treatment can be tolerated or where immediate hospital admission is warranted.
  • Rifampicin-resistant bacteria detected in the sputum susceptibility testing at Screening.
  • Treatment received with any drug active against M. tuberculosis within the 3 months prior to Screening.
  • History of allergy to any nitro-imidazole derivates, rifamycin derivatives, isoniazid derivatives, pyrazinamide or ethambutol.
  • Clinical evidence of severe extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis).
  • Evidence of pulmonary silicosis, lung fibrosis, or other lung condition considered as severe by the investigator (other than TB).
  • Presence of chronic obstructive pulmonary disease or asthma.
  • Any clinically relevant concomitant conditions or renal impairment characterized by serum creatinine levels >= 1.5xULN or hepatic impairment or alcohol abuse characterized by ALT and/or aspartate transferase (AST) levels 3xULN and/or gamma-glutamyl transpeptidase (GGT) levels 3xULN of the laboratory reference range.
  • Known or suspected alcohol or drug abuse, that is, abuse sufficient enough to compromise the safety or cooperation of the patient, in the opinion of the investigator, and as evident by a positive urine drug screen.
  • Neuropathy, psychosis or epilepsy.
  • Clinically relevant changes in the ECG such as atrioventricular (AV) block, prolongation of the QRS complex >120 milliseconds (in both male and female patients), or QTcB interval >430 milliseconds in male patients and >450 milliseconds in female patients. Family history of long QT syndromes and/or Torsade de Pointes.
  • History of or current clinically relevant cardiovascular disorder such as hypokalaemia, heart failure, coronary heart disease, hypertension, arrhythmia or symptom strongly suggestive of such a problem (for example, syncope or palpitations), tachyarrhythmia or status after myocardial infarction.
  • Known bleeding disorders or family history of bleeding disorders.
  • Diabetes treated with insulin.
  • Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).
  • Any diseases or conditions in which the use of rifampicin, isoniazid, pyrazinamide or ethambutol is contra-indicated.
  • Any disease or conditions in which any of the medicinal products listed in the protocol, is used. Treatment received with quinolones and prednisolone within 3 months prior to Screening.
  • Administration of an IMP within 1 month prior to Screening.
  • Pregnancy, breast-feeding, or planning to conceive or father a child within the timeframe described in the informed consent form.
  • Recent use of methadone, benzodiazepines, cocaine, amphetamine/metamphetamine, tetrahydrocannabinol, barbiturates, tricyclic antidepressants, and opiates as determined by a urine drug screen.
  • Helper/inducer T lymphocyte (CD4 cell) count of <=350x106/L.
  • Use of antiretroviral therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00401271

South Africa
Tiervlei Trial Center, Karl Bremer Hospital
Bellville, W Cape, South Africa, 7531
University of Cape Town Lung Institute
Mowbray, W Cape, South Africa, 7700
Medical Research Council
Durban, South Africa, 4000
Sponsors and Collaborators
Otsuka Frankfurt Research Institute GmbH
Principal Investigator: Andreas H Diacon, Dr. Tiervlei Trial Center
Principal Investigator: Roxana Rustomjee, Dr. Medical Research Council
Principal Investigator: Rodney Dawson, Dr. University of Cape Town Lung Institute Identifier: NCT00401271     History of Changes
Other Study ID Numbers: 242-06-101
First Posted: November 20, 2006    Key Record Dates
Last Update Posted: March 7, 2007
Last Verified: March 2007

Additional relevant MeSH terms:
Tuberculosis, Pulmonary
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections